Jones Financial Companies Lllp Purchases 4,312 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Jones Financial Companies Lllp raised its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 303.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,733 shares of the biotechnology company’s stock after acquiring an additional 4,312 shares during the quarter. Jones Financial Companies Lllp’s holdings in ADMA Biologics were worth $98,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of ADMA. Larson Financial Group LLC bought a new stake in ADMA Biologics during the 3rd quarter valued at approximately $31,000. GAMMA Investing LLC boosted its position in ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 967 shares in the last quarter. National Bank of Canada FI bought a new stake in ADMA Biologics during the 3rd quarter valued at approximately $35,000. Harvest Fund Management Co. Ltd bought a new stake in ADMA Biologics during the 3rd quarter valued at approximately $62,000. Finally, Nisa Investment Advisors LLC boosted its position in ADMA Biologics by 133.9% during the 4th quarter. Nisa Investment Advisors LLC now owns 7,378 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 4,224 shares in the last quarter. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Stock Performance

Shares of ADMA opened at $18.43 on Monday. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The business’s 50 day moving average price is $16.67 and its 200-day moving average price is $17.96. ADMA Biologics, Inc. has a 52 week low of $5.88 and a 52 week high of $23.64. The stock has a market cap of $4.36 billion, a P/E ratio of 65.82 and a beta of 0.60.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.